Celiac disease antigens

Open tTG™

(inhibited human tissue transglutaminase, stabilized in its open conformation, recombinantly produced in insect cells)
Quantity Unit Price Status
250 µg 550 € Available
1 mg 1650 € Available
Documents
Art. No.
T051
Background info
Human tissue transglutaminase recombinantly produced in insect cells, conjugated with a specific inhibitor in order to stabilize the open conformation. Thereby new epitopes become accessible.

open tTG tissue transglutaminase T051 by Zedira
Molecular Weight
78 kDa (Val224-allele, Kanchan et al., Biochem. J. 2013, 455:261–72)
Purity
> 95 % by SDS-PAGE under reducing conditions
Appearance
Liquid
Description
Human tissue transglutaminase recombinantly produced in insect cells, conjugated with a specific inhibitor in order to stabilize the open conformation. Thereby new epitopes become accessible.
Formulation
The Open tTGTM is supplied in 20 mM Tris-HCl pH 7.2, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 10% Glycerol
Application
Open tTGTM may be used for immunoprecipitation and detection of autoantibodies in body fluid samples from patients suffering from autoimmune diseases like psoriasis or gluten sensitive enteropathy.
Storage
Upon receipt, store immediately at -80°C. Stability is given for at least 10 years when stored at -80°C (see retest date on Certificate of Analysis), with potential to date extend after retesting. If storage at -80°C is not possible, storage at ≤ -20°C is recommended. While no formal stability data are available at -20°C, according to our overall experience stability is still given.
Store undiluted working aliquots preferably at -80°C (if not possible at ≤ -20°C, see comment above). Storage of diluted aliquots may result in severe activity loss.
Avoid repeated freezing and thawing.
Reference(s)
Lortat-Jacob H. et al., J Biol Chem. 2012: 18005–18017
Lindfors K. et al., J Clin Immunol. 2011: 436-42
Pallav K. et al., Dig Liver Dis. 2012: 375-8
Giannetto et al. Biosens Bioelectron. 2014, 62:325-30
Protein Data Bank (PDB) entry: 3S3P

Further please refer to:
“Inhibitors of transglutaminase 2: A therapeutic option in celiac disease”
(http://zedira.com/data/newsletter/newsletter_20080902.pdf)
Note
Intended for research use only, not for use in human or therapeutic applications. Usage in celiac disease diagnostic products may require a license for European Patent 0912898 and US Patent US 8,808,980 B2.

News

Blog

Events